Zaroxolyn and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Zaroxolyn (metolazone), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Lasix, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Nosebleed when taking Zaroxolyn. It is created by eHealthMe based on reports of 5,225 people who have side effects when taking Zaroxolyn from the FDA, and is updated regularly.

What is Zaroxolyn?

Zaroxolyn has active ingredients of metolazone. It is often used in high blood pressure. eHealthMe is studying from 5,244 Zaroxolyn users. Check the latest studies of Zaroxolyn.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 17, 2026

5,225 people reported to have side effects when taking Zaroxolyn.
Among them, 91 people (1.74%) have Nosebleed.

Among these 91 people:

How long have people been on Zaroxolyn when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Zaroxolyn? *

female: 45.05 %
male: 54.95 %

What is the age of people who have Nosebleed when taking Zaroxolyn? *

What are other drugs people take besides Zaroxolyn? *

What are other side effects people have besides Nosebleed? *

Cardiac Failure Congestive: 23 people, 25.27%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 18 people, 19.78%
Dyspnea (difficult or laboured breathing): 18 people, 19.78%
Joint Pain: 16 people, 17.58%
Nausea (feeling of having an urge to vomit): 15 people, 16.48%
Headache (pain in head): 15 people, 16.48%
Acute Kidney Failure: 14 people, 15.38%
Chest Pain: 13 people, 14.29%
Fall: 13 people, 14.29%
International Normalised Ratio Increased: 12 people, 13.19%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 22 people, 24.18%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 12 people, 13.19%
Pain: 10 people, 10.99%
High Blood Cholesterol: 8 people, 8.79%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 8 people, 8.79%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 6 people, 6.59%
Enlarged Prostate: 6 people, 6.59%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 5.49%
Atrial Thrombosis (blood clot that develops in an artery): 4 people, 4.40%
Stress And Anxiety: 3 people, 3.30%

* Approximation only. Some reports may have incomplete information.

Do you take Zaroxolyn and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zaroxolyn:

Zaroxolyn (5,244 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Zaroxolyn:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on metolazone (the active ingredients of Zaroxolyn) and Zaroxolyn (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.